VIVUS Announces the Return of Marketing andDistribution Rights for AstraZeneca Territory
October 7, 1999 04:01 PM
MOUNTAIN VIEW, Calif.--(BW HealthWire)--Oct. 7, 1999--VIVUS International, Ltd. (a subsidiary of VIVUS, Inc.)VVUS and AstraZeneca today announced the return to VIVUS of the marketing and distribution rights for MUSE(R) (alprostadil). This decision follows a change in product strategies due to the recent merger of Astra AB and Zeneca Group PLC.
AstraZeneca will continue to handle patient and physician inquiries and ensure product supply while VIVUS pursues strategic alternatives regarding marketing and distribution of MUSE in Europe, Australia, New Zealand, Central America and South America.
VIVUS, Inc. is the developer and manufacturer of MUSE (alprostadil) and ACTIS(TM), two innovations in the treatment of men with erectile dysfunction ("ED"), also known as impotence. The Company's objective is to become a global leader in the development and commercialization of innovative therapies for the treatment of sexual dysfunction and urologic disorders in men and women. VIVUS has ongoing research and development programs, and has completed its Phase III clinical trial for ALIBRA(TM), its second-generation male ED treatment. The Company expects to file a New Drug Application for ALIBRA by the end of 1999.
Note to editors and investors:
The company will announce its quarterly financial results followed by a conference call on October 20, 1999. Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719).
|
